Post-HSCT Maintenance Treatment Using Entrectinib for an AML Patient Accompanied with ETV6::NTRK3: A Case Report

Abstract

The neurotrophic receptor tyrosine kinase (NTRK) gene fusions occur in a large number of solid tumors and tropomyosin receptor kinase (TRK) inhibitors exhibit attractive antitumor activity. However, the occurrence of NTRK fusions is rare in hematological malignancies, and just a few cases or pre-clinical researches have been reported. This case report presents a refractory acute myeloid leukemia (AML) patient, accompanied with ETV6::NTRK3, was failed by traditional chemotherapy, then entered long-term remission after hematopoietic stem cell transplantation (HSCT) and maintenance therapy with entrectinib. It was the first successful use of the TRK inhibitor in an AML patient after HSCT.

Keywords:

• entrectinib
• acute myeloid leukemia
• ETV6::NTRK3
• allogeneic hematopoietic stem cell transplantation

Data Sharing Statement

All data related to the study are included in the paper.

Ethics Approval

This study was approved by the ethical committee of the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences.

Informed Consent Statement

Written informed consent has been obtained from the patient to publish this paper.

Acknowledgments

The authors are grateful to the patient for his participation.

Author Contributions

All authors contributed to proposing the treatment strategy, data analysis, drafting or revising the manuscript. All authors reviewed and agreed on the version of the article to be published, the journal to which the manuscript has been submitted, and agreed to be accountable for the contents of the article.

Disclosure

The authors report no conflicts of interest in this work.

Additional information

Funding

The authors received no specific funding for this study.